Sunday 20 October, 2019
Edition: English (US)
MMJ Observer
Tag Archives: OTCMKTS:AXIM

Axim Biotechnologies Inc. (OTCMKTS:AXIM) has announced that they have received a seventh private label purchase order for the company’s proprietary CBD chewing gum in the past five months. The purchase order equals products sales of chewing...

By Steven Russell on Jul 15th, 2019

Axim Biotechnologies Inc (OTCMKTS:AXIM) has entered into a pact with Impression Healthcare Ltd (IHL) to distribute all of the AXIM® Biotech products in New Zealand and Australia. As per the terms of the pact, both the firms will engage in...

By Melissa Kay on Oct 1st, 2018

Axim Biotechnologies Inc (OTCMKTS:AXIM) and Revive Therapeutics Ltd have signed an exclusive distribution and license agreement. Revive Therapeutics is a Canadian cannabis companies focused on research, development and marketing of novel cannabis...

By Sophia T on Sep 21st, 2018

Axim Biotechnologies Inc (OTCMKTS:AXIM) has been issued with a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for a methodology of extraction and purification of the cannabinoid molecule delta-9-tetrahydrocannabinol,...

By Jon Slotnick on Aug 14th, 2018

With pro-cannabis legislation gaining steam across the United States, investors across the globe have been seeking opportunities to put their hands in the figurative cannabis cookie jar. More than half of the states have legalized medical marijuana,...

By Emily Gibson on Dec 18th, 2016

Recently, Axim Biotechnologies Inc (OTCMKTS:AXIM) has been named as one of the five best stocks in the biotechnology industry this year, along with CoLucid Pharmaceuticals Inc (NASDAQ:CLCD), Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP),...

By Sophia T on Dec 2nd, 2016

Don’t Just Beat the Market, Crush It!

Let’s put the power in your hands. I do the work, find, and reveal up to 10 simple trades each week that can make you a killing. Learn my system. Trade my system. Keep all the profits.
**Limited only for the next 47 visitors
Click Me